141 related articles for article (PubMed ID: 24388871)
1. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications.
Kumar J; Ward AC
Biochim Biophys Acta; 2014 Apr; 1845(2):117-25. PubMed ID: 24388871
[TBL] [Abstract][Full Text] [Related]
2. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
3. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
Jia ZH; Jia Y; Guo FJ; Chen J; Zhang XW; Cui MH
PLoS One; 2017; 12(8):e0183622. PubMed ID: 28859117
[TBL] [Abstract][Full Text] [Related]
6. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
[TBL] [Abstract][Full Text] [Related]
7. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
8. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
Wang SW; Sun YM
Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 trans-signalling induces vascular endothelial growth factor synthesis partly via Janus kinases-STAT3 pathway in human mesothelial cells.
Yang X; Lin A; Jiang N; Yan H; Ni Z; Qian J; Fang W
Nephrology (Carlton); 2017 Feb; 22(2):150-158. PubMed ID: 26869278
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of STAT3 in breast cancer cells: A review.
Banerjee K; Resat H
Int J Cancer; 2016 Jun; 138(11):2570-8. PubMed ID: 26559373
[TBL] [Abstract][Full Text] [Related]
11. SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL.
Li F; Zhang Z; Cheng T; Wei R; Dai Y; Lv M; Luo D; Zhu X; Ma D; Xi L; Dong Q; Ma X
Amino Acids; 2016 Jan; 48(1):91-101. PubMed ID: 26255282
[TBL] [Abstract][Full Text] [Related]
12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
13. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
Wang S; Zhang W
Tumour Biol; 2016 May; 37(5):6561-9. PubMed ID: 26638167
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Kumar J; Fraser FW; Riley C; Ahmed N; McCulloch DR; Ward AC
Br J Cancer; 2014 Jan; 110(1):133-45. PubMed ID: 24220695
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 as a therapy target in oral squamous carcinoma.
Culig Z
Expert Opin Ther Targets; 2013 Jan; 17(1):53-9. PubMed ID: 23101455
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas.
Osuka K; Watanabe Y; Usuda N; Aoyama M; Iwami K; Takeuchi M; Watabe T; Takayasu M
J Neurotrauma; 2017 Jun; 34(11):1996-2000. PubMed ID: 28027695
[TBL] [Abstract][Full Text] [Related]
17. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
Gupta M; Babic A; Beck AH; Terry K
Hum Pathol; 2016 Aug; 54():82-91. PubMed ID: 27068525
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
19. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
[TBL] [Abstract][Full Text] [Related]
20. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis.
Chen Q; Xu B; Lan L; Yang D; Yang M; Jiang J; Lu B; Shen Y
Sci Rep; 2017 Aug; 7(1):8769. PubMed ID: 28821817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]